In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Selected Start-Ups (6/01)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: Archemix Corp. will use its proprietary nucleic acid engineering technology to build protein detection chips and multiplexed assays for use in drug discovery. Gel-Del Technologies Inc. is developing protein-based biomaterials for making implanted medical devices more acceptable to the human body. Neuro Therapeutics Inc. was spun out of the University of British Columbia to commercialize therapies for stimulating repair of injured neurons after traumatic injury of the spinal cord or brain. OncoGenex Technologies Inc. aims to develop and commercialize therapeutics for hormone-independent prostate cancer. Rejuvenon Corp. aims to turn back the hands of time with drugs to treat or prevent disorders related to aging. A new entrant in the cardiovascular diagnostics arena, Belgium's Thermocore Medical Systems NV is developing a thermographic catheter-based system to localize and visualize unstable coronary plaque.

You may also be interested in...

Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared

Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.

UK Responsible Person, EU ARs and Northern Ireland: The View From MedTech Europe

GSK Aims To Launch 13 Blockbusters In Five Years

GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts